Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

IMPORTANCE: Anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immune checkpoint blockade (ICB) constitutes the therapeutic backbone for multiple malignant neoplasms. People living with HIV (PLWH) have routinely been excluded from ICB clinical trials, thus inhibiting broad im...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Netw Open
Egile Nagusiak: Reuss, Joshua E., Stern, Diana, Foster, Jared C., Ramaswami, Ramya, Lurain, Kathryn, Chen, Helen X., Streicher, Howard, Kem, Ravie, Little, Richard F., Sharon, Elad
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2020
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709086/
https://ncbi.nlm.nih.gov/pubmed/33258905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.27110
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak